The word capsule refers to any kind of small container, especially one that is round or cylindrical. Capsules consist of two pieces that fit together to contain either a powder, jelly, or liquid inside. The two external pieces may be the same color or contrasting colors.
It may take longer to feel the beneficial effects of CBD when taken as a softgel than taking it under the tongue. CBD softgels and capsules take extra time to breakdown in your digestive tract. This is called the first-pass effect. This often decreases the potency of CBD absorption in the human body.
What is a CBD Capsule?
Few consumers know the difference between CBD softgels and CBD capsules. They’re used to popping pills. There are subtle differences between softgels, capsules, and CBD pills – enough differences that you should be aware of when choosing a CBD product to add to your daily regime. Let’s compare the differences between softgels and capsules, so you understand how they impact the efficacy of your CBD routine.
Some common over the counter medicines that use softgels are gas relief products such as Phazyme or Gas-X, and fish oil supplements and omega oil softgels. Softgels themselves usually have a neutral flavor. They are more expensive to manufacture when compared to capsules or tinctures.
Capsules usually have a neutral flavor and may or may not be sealed at the edges. Probiotics are one common supplement you’ll often find in capsule form. Omeprazole is a well-known capsule on the market.
Since some CBD oils contain trace amounts of THC, you should avoid driving or using heavy machinery when taking CBD oil, particularly when first starting treatment or using a new brand.
In addition, the stroke volume (the amount of blood remaining in the heart after a heartbeat) was significantly reduced, meaning that the heart was pumping more efficiently.
The tricky part is calculating the exact amount of CBD per milliliter of oil. Some tinctures have concentrations of 1,500 mg per 30 mL, while others have 3,000 mg per mL (or more).
Scientists believe that CBD reduces nerve pain by binding to glycine receptors in the brain that regulate the speed at which nerve signals pass between nerve cells.
Remember, because CBD oils are largely unregulated, there is no guarantee that a product is either safe or effective.
In June 2018, the U.S. Food and Drug Administration (FDA) approved Epidiolex, a CBD oral solution used for the treatment of certain rare forms of epilepsy in children under 2—Dravet syndrome and Lennox-Gastaut syndrome. Both are exceptionally rare genetic disorders causing lifelong catastrophic seizures that begin during the first year of life.
CBD oil may benefit those with drug addiction, suggests a 2015 review of studies published in Substance Abuse.
Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006;399(1-2):91-5. View abstract.
Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 2011;51(5):1054-61. View abstract.
Over 80 chemicals, known as cannabinoids, have been found in the Cannabis sativa plant. Delta-9-tetrahydrocannabinol (THC) is the most famous ingredient in cannabis. But CBD is obtained from hemp, a form of the Cannabis sativa plant that only contains small amounts of THC. CBD seems to have effects on some chemicals in the brain, but these are different than the effects of THC.
Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017 Sep;58(9):1586-92. View abstract.
Maghfour J, Rundle CW, Rietcheck HR, et al. Assessing the effects of topical cannabidiol in patients with atopic dermatitis. Dermatol Online J. 2021;27(2):13030/qt8h50k2vs. View abstract.
Overview. GW Pharmaceuticals Web site. Available at: https://www.gwpharm.com/about-us-overview.aspx. Accessed: May 31, 2015.
Heussler H, Cohen J, Silove N, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J Neurodev Disord. 2019;11(1):16. View abstract.